Abstract:During past 3 decades, nuclear medicine has flourished as vibrant and independent medical specialty in Iran. Since that time, more than 200 nuclear physicians have been trained and now practicing in nearly 158 centers throughout the country. In the same period, Tc-99m generators and variety of cold kits for conventional nuclear medicine were locally produced for the first time. Local production has continued to mature in robust manner while fulfilling international standards. To meet the ever-growing demand at the national level and with international achievements in mind, work for production of other Tc-99m-based peptides such as ubiquicidin, bombesin, octreotide, and more recently a kit formulation for Tc-99m TRODAT-1 for clinical use was introduced. Other than the Tehran Research Reactor, the oldest facility active in production of medical radioisotopes, there is one commercial and three hospital-based cyclotrons currently operational in the country. I-131 has been one of the oldest radioisotope produced in Iran and traditionally used for treatment of thyrotoxicosis and differentiated thyroid carcinoma. Since 2009, (131)I-meta-iodobenzylguanidine has been locally available for diagnostic applications. Gallium-67 citrate, thallium-201 thallous chloride, and Indium-111 in the form of DTPA and Oxine are among the early cyclotron-produced tracers available in Iran for about 2 decades. Rb-81/Kr-81m generator has been available for pulmonary ventilation studies since 1996. Experimental production of PET radiopharmaceuticals began in 1998. This work has culminated with development and optimization of the high-scale production line of (18)F-FDG shortly after installation of PET/CT scanner in 2012. In the field of therapy, other than the use of old timers such as I-131 and different forms of P-32, there has been quite a significant advancement in production and application of therapeutic radiopharmaceuticals in recent years. Application of (131)I-meta-iodobenzylguanidine for treatment of neuroblastoma, pheochromocytoma, and other neuroendocrine tumors has been steadily increasing in major academic university hospitals. Also (153)Sm-EDTMP, (177)Lu-EDTMP, (90)Y-citrate, (90)Y-hydroxyapatite colloid, (188/186)Re-sulfur colloid, and (188/186)Re-HEDP have been locally developed and now routinely available for bone pain palliation and radiosynovectomy. Cu-64 has been available to the nuclear medicine community for some time. With recent reports in diagnostic and therapeutic applications of this agent especially in the field of oncology, we anticipate an expansion in production and availability. The initiation of the production line for gallium-68 generator is one of the latest exciting developments. We are proud that Iran would be joining the club of few nations with production lines for this type of generator. There are also quite a number of SPECT and PET tracers at research and preclinical stage of development preliminarily introduced for possible future clinical applications. Availability of fluorine-18 tracers and gallium-68 generators would no doubt allow rapid dissemination of PET/CT practices in various parts of our large country even far from a cyclotron facility. Also, local production and availability of therapeutic radiopharmaceuticals are going to open exciting horizons in the field of nuclear medicine therapy. Given the available manpower, local infrastructure of SPECT imaging, and rapidly growing population, the production of Tc-99m generators and cold kit would continue to flourish in Iran.

State of the Art in Cyclotrons for Radionuclide Production in Biomedicine

ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine

New developments for theranostic radioisotope production with solid targets at the Bern medical cyclotron

Commercial cyclotrons. Part I: Commercial cyclotrons in the energy range 10–30 MeV for isotope production

Production of Medical Radioisotopes with High Specific Activity in Photonuclear Reactions with $γ$ Beams of High Intensity and Large Brilliance

Design study of an ultra-compact superconducting cyclotron for isotope production

Cyclotron production of manganese-52: a promising avenue for multimodal PET/MRI imaging

Radiobiology with cyclotron proton beams: A viability study

Investigation of production of medical 82Sr and 68Ge for 82Sr/82Rb and 68Ge/68Ga generators via proton accelerator

Investigation of Production Possibility of Medical Isotope 155Tb on Cyclotron C18/18

From cyclotrons to chromatography and beyond: a guide to the production and purification of theranostic radiometals

Nuclear data for light charged particle induced production of emerging medical radionuclides

Study of thulium-167 cyclotron production: a potential medically-relevant radionuclide

Hybridised production of technetium-99m and technetium-101 with fluorine-18 on a low-energy biomedical cyclotron

Analysis and optimization of production conditions for 18F production using a medical cyclotron

Radioisotopes production using lasers: from basic science to applications

Medical Isotope Production with the IsoDAR Cyclotron

44Sc production from enriched 47TiO2 targets with a medical cyclotron

Production and Clinical Applications of Radiopharmaceuticals and Medical Radioisotopes in Iran

Application of therapeutic linear accelerators for the production of radioisotopes used in nuclear medicine

Practical experience and challenges in the operation of medical cyclotron